Craniometrix vs Amgen
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF dementia care coordination platform with Johns Hopkins MIND at Home partnership; YC $6.5M with $1.9M revenue connecting patients and caregivers through virtual care navigation for Alzheimer's management.
About
Craniometrix is a San Francisco-based digital health company providing virtual dementia care coordination — connecting dementia patients, family caregivers, and healthcare providers through a telemedicine platform that delivers cognitive assessment, care planning, caregiver education, and ongoing care management for Alzheimer's and related dementia conditions. Founded by CEO Nikhil Patel and backed by Y Combinator with $6-6.5 million raised from Y Combinator, Quiet Capital, and Defy.vc, Craniometrix generated $1.9 million in revenue in 2024 and partners with the Johns Hopkins MIND at Home program — a validated community-based dementia care model developed by Johns Hopkins University School of Medicine.
Amgen (AMGN) reported $33.4B revenue in FY2024, up 19% YoY (post-Horizon acquisition). Top-5 global biotech. 10+ blockbuster drugs. ~24,000 employees. HQ: Thousand Oaks, CA. Market cap ~$130B.
About
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologics and brought landmark medicines including Epogen, Neupogen, and Enbrel to market. The company reported revenues of $33.4B in FY2024, up 19% year-over-year, boosted by the transformational $28B acquisition of Horizon Therapeutics in October 2023.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.